Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
HRTXthis companyHeron Therapeutics, Inc.	$0.37	-10.83×	15.12×	1.4×	-18.38×	-4735.4%	73.3%	-1.6%	-13.0%	-140.9%	-1.6%	-12.9%	9.81×	-6.26×	0×	2.48×	0.0%	2	-9.84	2	C
CHRSCoherus Oncology, Inc.	$0.81	-0.98×	2.8×	4.05×	-0.72×	-124.2%	57.9%	-425.7%	-403.8%	-279.1%	-151.8%	-81.0%	0.66×	0.29×	-19.95×	1.46×	0.0%	2	-12.02	1	C-
IVVDInvivyd, Inc.	$0.58	-8.23×	1.76×	7.96×	-3.99×	1722.3%	93.0%	-104.0%	-98.2%	-21.7%	-22.8%	-13.7%	0.01×	4.45×	0×	7.24×	0.0%	1	-4.47	3	B
NTHINeonc Technologies Holdings, Inc.	$3.60	-2.56×	-9.07×	3,973.02×	-2.77×	-122.3%	100.0%	-145459.4%	-155404.4%	355.0%	519.7%	-13.1%	-0.36×	-0.1×	-23.23×	0.07×	0.0%	2	-66.25	2	C
OABIOmniAb, Inc.	$5.36	-3.25×	0.79×	11.26×	-4.6×	-105.3%	-18.2%	-383.1%	-347.0%	-24.3%	-24.2%	-17.6%	0.08×	0.12×	0×	4.02×	0.0%	4	9.56	2	C
PLXProtalix BioTherapeutics, Inc.	$2.53	-21.4×	2.93×	2.68×	-45.74×	-235.1%	47.8%	-10.4%	-12.5%	-13.7%	-9.6%	-9.6%	0.17×	2.15×	-4.62×	2.51×	0.0%	4	0.74	4	A-
Peer median	—	-3.25×	1.76×	7.96×	-3.99×	-122.3%	57.9%	-383.1%	-347.0%	-21.7%	-22.8%	-13.7%	0.08×	0.29×	-4.62×	2.51×	0.0%	2	-4.47	2	—